• Gyre Therapeutics outlined a post-Cullgen strategy to use China operations to accelerate discovery, early validation, manufacturing, development, commercialization.
• F351 (hydronidone) CHB-associated liver fibrosis Phase 3 met the primary endpoint; fibrosis regression at Week 52 was 52.85% vs 29.84% (p=0.0002).
• Key secondary endpoint met; inflammation improvement without fibrosis progression was 49.57% vs 34.82% (p=0.0246).
• F351 NDA accepted by China’s NMPA in May 2026; U.S. IND filed for MASH with Phase 2 start anticipated in 2027.
• ETUARY (pirfenidone) positioned as a market-leading antifibrotic franchise with planned line extensions including pneumoconiosis, radiation-induced lung injury.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.